Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402

J Cancer Res Clin Oncol. 2020 Nov;146(11):2949-2956. doi: 10.1007/s00432-020-03270-2. Epub 2020 May 27.

Abstract

Purpose: Considering the initial treatment of hepatocellular carcinoma (HCC), the best prognostic index for Child-Pugh classes B and C (CP-BC) patients has not been yet established. This study aimed to elucidate the risk factors for disease-free survival (DFS) and overall survival (OS) in multicenter patients with a poor liver functional reserve after curative treatment.

Methods: Between April 2000 and April 2014, 212 CP-BC patients who received treatment in five high-volume centers in Japan were included in this study. CP-B and C patients were 206 and 6, respectively. Cox proportional hazard regression analyses for DFS and OS were performed to estimate the risk factors.

Results: The mean observation time was 1132 days. Mean Child-Pugh score and indocyanine green retention rate at 15 min were 7.5 and 31.5%, respectively. Histological chronic hepatitis and liver cirrhosis were observed in 20% and 74% patients, respectively. In the multivariate analysis, the risk factors for DFS were des-gamma-carboxy prothrombin (DCP) [hazard ratio (HR), 1.6; P = 0.012] and treatment without liver transplantation. Moreover, DCP was identified as an independent risk factor for OS (HR, 1.7; P = 0.01). Tumor size, number, tumor thrombus, Milan criteria, liver cirrhosis, and treatment without liver transplantation were not identified as risk factors for OS. The 5-year OS in patients with high serum DCP levels (< 90 mAU/mL) was significantly better than that in those with low serum DCP levels (P = 0.003).

Conclusions: Serum DCP value before treatment predicted both DFS and OS in CP-BC patients with HCC.

Keywords: Ablation therapy; Child–pugh class B and C; Hepatectomy; Hepatocellular carcinoma; Liver transplatation; Poor liver functional reserve; Safety.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Biomarkers / blood*
  • Biomarkers, Tumor / blood*
  • Carcinoma, Hepatocellular / blood*
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Liver Neoplasms / blood*
  • Liver Neoplasms / mortality
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Protein Precursors / blood*
  • Prothrombin

Substances

  • Biomarkers
  • Biomarkers, Tumor
  • Protein Precursors
  • acarboxyprothrombin
  • Prothrombin